PP259 - YEAST MANNAN SUPPLEMENTATION INCREASES STOOL FREQUENCY IN ADULTS WITHOUT GASTROINTESTINAL SYMPTOMS

PP259

YEAST MANNAN SUPPLEMENTATION INCREASES STOOL FREQUENCY IN ADULTS WITHOUT GASTROINTESTINAL SYMPTOMS

M. L. Moreno^1,*, T. A. Tompkins², W. J. Dahl¹

¹Food Science and Human Nutrition, University of Florida, Gainesville, United States, ²Lallemand Bio Ingredients, Montreal, Canada

Rationale: Prebiotics with the potential to improve gastrointestinal (GI) function without inducing unpleasant symptoms are needed. The aim of the study was to determine if yeast mannan (YM) supplementation would increase stool frequency in adults reporting ≤ 1 stool per day.

Methods: A 6-week, double-blinded, parallel, randomized clinical trial was conducted. After a 2-week baseline period, participants were randomized to consume 12 g/d of either YM or a macronutrient-matched control containing non-cell-wall yeast extract and maltodextrin for 4 weeks. Participants completed a daily online survey of stool frequency and GI symptoms (0 = none to 3 = severe) and the weekly Digestion-associated Quality of Life Questionnaire (DQLQ). Participants consumed two blue-dyed muffins and collected all stools during the final three days of baseline and intervention. Whole gut transit time was estimated as the interval from dye ingestion to the first appearance of blue-colored stool. Generalized linear mixed models were used to assess stool frequency, symptoms, and DQLQ score, and transit time by t-test.

Results: Participants (n=52, 31±15y) completed the study. Stool frequency increased from 0.9±0.1 stools/day at baseline to 1.2±0.1 for YM (p<0.001), and to a lesser extent for the control (baseline: 0.9±0.1; intervention: 1.0±0.1; p<0.05). Nausea, although infrequently reported, increased with YM (0.03±0.07 to 0.27±0.06) but not control (0.10±0.06 to 0.16±0.06) (p<0.05). Comparing intervention weeks 5 and 6 to baseline, constipation symptom improved with YM (p<0.05). Otherwise, there were no significant changes from baseline or between-group differences for GI symptoms or DQLQ score. Change in transit time did not differ between YM (D=-4 h) and control (D=+0.5 h).

Conclusion: Adults experienced a 33% increase in stool frequency with YM supplementation and minimal GI symptoms, with no overall changes in DQLQ or transit time.

Disclosure of Interest: None declared